Skip to main content

Wall Street is not exactly impressed with the Pfizer-Mylan deal

EpiPen-maker Mylan NV is merging with Pfizer Inc.’s off-patent drugs business, and Wall Street is not fully on board.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.